Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 172.45
SRPT's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 172.45 )
SRPT' s 10-Year Cash to Debt Range
Min: 4.43   Max: No Debt
Current: 172.45

Equity to Asset 0.89
SRPT's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 0.89 )
SRPT' s 10-Year Equity to Asset Range
Min: -0.09   Max: 0.98
Current: 0.89

-0.09
0.98
F-Score: 4
Z-Score: 12.88
M-Score: -1.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -634.95
SRPT's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: -634.95 )
SRPT' s 10-Year Operating margin (%) Range
Min: -28680.87   Max: -71.16
Current: -634.95

-28680.87
-71.16
Net-margin (%) -787.57
SRPT's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: -787.57 )
SRPT' s 10-Year Net-margin (%) Range
Min: -27020   Max: -4.93
Current: -787.57

-27020
-4.93
ROE (%) -45.30
SRPT's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: -45.30 )
SRPT' s 10-Year ROE (%) Range
Min: -296.67   Max: -7.47
Current: -45.3

-296.67
-7.47
ROA (%) -38.41
SRPT's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: -38.41 )
SRPT' s 10-Year ROA (%) Range
Min: -261.76   Max: -4.26
Current: -38.41

-261.76
-4.26
ROC (Joel Greenblatt) (%) -599.93
SRPT's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: -599.93 )
SRPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2075   Max: -269.31
Current: -599.93

-2075
-269.31
Revenue Growth (%) -35.80
SRPT's Revenue Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: -35.80 )
SRPT' s 10-Year Revenue Growth (%) Range
Min: -63.2   Max: 383.5
Current: -35.8

-63.2
383.5
EBITDA Growth (%) 35.80
SRPT's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 35.80 )
SRPT' s 10-Year EBITDA Growth (%) Range
Min: -36.3   Max: 43.4
Current: 35.8

-36.3
43.4
EPS Growth (%) 23.90
SRPT's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 23.90 )
SRPT' s 10-Year EPS Growth (%) Range
Min: -62.4   Max: 46.9
Current: 23.9

-62.4
46.9
» SRPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SRPT Guru Trades in Q3 2013

Steven Cohen 960,300 sh (+1816.77%)
George Soros 665,274 sh (+56.28%)
Andreas Halvorsen Sold Out
Columbia Wanger 1,431,000 sh (-19.92%)
» More
Q4 2013

SRPT Guru Trades in Q4 2013

Columbia Wanger 2,635,000 sh (+84.14%)
Steven Cohen 711,777 sh (-25.88%)
George Soros 233,000 sh (-64.98%)
» More
Q1 2014

SRPT Guru Trades in Q1 2014

Columbia Wanger 2,633,000 sh (-0.08%)
Steven Cohen 641,600 sh (-9.86%)
George Soros 25,000 sh (-89.27%)
» More
Q2 2014

SRPT Guru Trades in Q2 2014

George Soros 680,000 sh (+2620%)
Columbia Wanger 2,633,000 sh (unchged)
Steven Cohen 272,100 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SRPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Add 2620%0.14%$22.18 - $38.91 $ 22.05-30%680000
George Soros 2014-03-31 Reduce -89.27%0.04%$17.91 - $30.29 $ 22.05-13%25000
George Soros 2013-12-31 Reduce -64.98%0.22%$12.89 - $53.81 $ 22.05-26%233000
George Soros 2013-09-30 Add 56.28%0.12%$30.906 - $47.97 $ 22.05-42%665274
George Soros 2013-03-31 Add 82.54%0.08%$23.97 - $36.95 $ 22.05-24%413329
George Soros 2012-12-31 Add 184.13%0.05%$14.99 - $44.93 $ 22.05-18%226429
Jean-Marie Eveillard 2012-03-31 Sold Out $4.5 - $9.6 $ 22.05264%0
Jean-Marie Eveillard 2011-12-31 Reduce -83.33%$3.24 - $6.54 $ 22.05338%50000
Jean-Marie Eveillard 2011-09-30 Add 50%$6.3 - $9.9 $ 22.05178%300000
Jean-Marie Eveillard 2011-06-30 New Buy$8.1 - $11.22 $ 22.05128%200000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.10
SRPT's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 3.10 )
SRPT' s 10-Year P/B Range
Min: 1.61   Max: 234
Current: 3.1

1.61
234
P/S 53.80
SRPT's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 53.80 )
SRPT' s 10-Year P/S Range
Min: 1.56   Max: 310
Current: 53.8

1.56
310
EV-to-EBIT -6.27
SRPT's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: -6.27 )
SRPT' s 10-Year EV-to-EBIT Range
Min: 8   Max: 49.3
Current: -6.27

8
49.3
Current Ratio 10.36
SRPT's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 10.36 )
SRPT' s 10-Year Current Ratio Range
Min: 0.76   Max: 36.25
Current: 10.36

0.76
36.25
Quick Ratio 10.36
SRPT's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 10.36 )
SRPT' s 10-Year Quick Ratio Range
Min: 0.76   Max: 36.25
Current: 10.36

0.76
36.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.70
SRPT's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 3.70 )
SRPT' s 10-Year Price/Net Cash Range
Min: 3.01   Max: 72.6
Current: 3.7

3.01
72.6
Price/Net Current Asset Value 3.70
SRPT's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 3.70 )
SRPT' s 10-Year Price/Net Current Asset Value Range
Min: 2.96   Max: 115.5
Current: 3.7

2.96
115.5
Price/Tangible Book 3.10
SRPT's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 3.10 )
SRPT' s 10-Year Price/Tangible Book Range
Min: 2.41   Max: 474
Current: 3.1

2.41
474
Price/Median PS Value 2.10
SRPT's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 2.10 )
SRPT' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 76.32
Current: 2.1

0.08
76.32
Forward Rate of Return (Yacktman) 19.46
SRPT's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. SRPT: 19.46 )
SRPT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.2   Max: 18.1
Current: 19.46

1.2
18.1

Business Description

Industry: »
Compare: » details
Traded in other countries:AB3A.Germany
Sarepta Therapeutics Inc was incorporated in the State of Oregon on July 22, 1980. The Company discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The Company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases.
» More Articles for SRPT

Headlines

Articles On GuruFocus.com
Insiders Are Buying Fate Therapeutics Oct 09 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Feb 16 2013 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Sep 02 2014
BioCryst to Launch NHP Ebola Drug Safety, Efficacy Studies 'Within Weeks' Aug 29 2014
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Aug 28 2014
SAREPTA THERAPEUTICS, INC. Financials Aug 26 2014
How Will We Know If The Ebola Drugs Worked? Aug 26 2014
Sarepta Enters into Partnership with Flagship Biosciences to Digitally Automate the Measurement of... Aug 21 2014
[$$] Cash In on Taser's Gains With Moves in Options Aug 19 2014
As Ebola Outbreak Expands, These Experimental Drugs Could See Action Aug 18 2014
Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss Aug 12 2014
[video] Biotechs race for Ebola cure Aug 11 2014
Biotechs That Might Benefit From Ebola Research Aug 11 2014
Tekmira Ebola Drug Hold Lifted By FDA, Stock Soars Aug 08 2014
Today's Dead Cat Bounce Stock Is Sarepta Therapeutics (SRPT) Aug 08 2014
FDA Moves On Tekmira's Ebola Drug While Sarepta's Sits Unused Aug 07 2014
[video] Ebola not easily spread: Doctor Aug 07 2014
[video] Pharma companies rush to help Ebola Aug 07 2014
Looking to trade on Ebola? Beware Aug 07 2014
Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today Aug 07 2014
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 07 2014
Sarepta Therapeutics Announces Second Quarter 2014 Financial Results and Recent Corporate... Aug 07 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK